Gsa Capital Partners LLP Lyell Immunopharma, Inc. Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 354,815 shares of LYEL stock, worth $337,074. This represents 0.04% of its overall portfolio holdings.
Number of Shares
354,815
Previous 25,610
1285.45%
Holding current value
$337,074
Previous $37,000
1224.32%
% of portfolio
0.04%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding LYEL
# of Institutions
122Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$19.2 Million30.81% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$14.3 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$14.3 Million13.96% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$12.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$9.57 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $235M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...